Concord Biotech Ltd (CONCORDBIO) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management expects full-year FY27 revenue growth to be 'slightly better' than the historical 18-19%, signaling confidence in sustained momentum after a strong first half.
- The company's core EBITDA margin is ~37-38%, with new ventures (injectables, US subsidiary) currently causing a ~400 basis point drag, which will reverse upon ramp-up.
- Capex is guided at INR 50-60 crores for the rest of FY27 and a similar amount for FY28, supporting future growth initiatives and capacity maintenance.
Performance Overview
- Reported strong performance with a 25% year-on-year revenue growth for Q2 FY27, maintaining momentum from the first half of the year.
- Broad-based growth was observed across all product categories (immunosuppressants, anti-infective, anti-fungal, oncology) and geographies.
- API business grew by 30% YoY, while the domestic formulations business saw a strong 29% YoY growth in the quarter.
- Successfully completed a US FDA inspection for the Unit 2 formulation facility and received ANVISA approval for the Unit 3 facility.
- Launched 'Inspira', a new dermatology division, to enter the science-led skin health solutions market.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.